GHRP-2 vs Ipamorelin: Potent vs Selective GH Release
Here is how these two compounds compare — based on published research, not marketing claims.
GHRP-2
255
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Ipamorelin
48
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
Both GHRP-2 and ipamorelin are growth hormone secretagogues that activate the ghrelin receptor. The difference is selectivity. GHRP-2 produces a powerful GH release but also spikes cortisol, prolactin, and appetite. Ipamorelin produces a slightly weaker GH pulse but barely touches anything else. This is the potency-versus-precision trade-off.
Key Differences
| Attribute | GHRP-2 | Ipamorelin |
|---|---|---|
| Evidence Level | Human Trials | Human Trials |
| Category | Growth Hormone Releasing Peptide | Growth Hormone Secretagogue |
| Human Data | Multiple human pharmacodynamic studies. Used clinically as a GH stimulation test. PSI rates L3. | Multiple human studies for GH stimulation and bone healing. PSI rates L3. |
| Safety Profile | Elevates cortisol and prolactin alongside GH. Strong appetite stimulation. More off-target effects than newer secretagogues. | Minimal off-target effects. Does not significantly raise cortisol or prolactin. Side effects are generally mild. |
| Key Limitations | Non-selective. Cortisol and prolactin elevation are undesirable for many applications. | GH release may be slightly less potent than GHRP-2 at equivalent doses. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
GHRP-2
Activates the ghrelin receptor (GHS-R1a) to stimulate GH release. Also stimulates cortisol and prolactin release and strongly increases appetite. It is a blunt instrument — effective but non-selective.
Ipamorelin
Activates the same ghrelin receptor as GHRP-2 but with notably clean selectivity. Raises GH without significantly affecting cortisol, prolactin, or aldosterone. Think of it as a precision tool versus GHRP-2's sledgehammer.
Same receptor, different precision. GHRP-2 activates the ghrelin receptor broadly, triggering GH release alongside cortisol, prolactin, and hunger. Ipamorelin activates the same receptor but somehow avoids most of the off-target effects. The pharmacological mechanism behind ipamorelin's selectivity is not fully understood, but the clinical observation is consistent across studies.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 303 indexed studies. Here are the key findings.
Both L3 with comparable publication counts. GHRP-2 has been used longer as a GH stimulation test in clinical settings. Ipamorelin has more recent pharmacological data emphasizing its selectivity advantage.
If maximizing GH pulse magnitude is the only priority, GHRP-2 produces a stronger response.
If minimizing cortisol and prolactin elevation matters, ipamorelin is clearly superior.
If appetite stimulation is desired (e.g., for underweight patients), GHRP-2's appetite effect is useful.
If appetite stimulation is a problem, ipamorelin avoids it.
Key Limitations
- •No direct head-to-head efficacy trial.
- •Both are non-FDA-approved research compounds.
- •GHRP-2's cortisol elevation may limit its suitability for chronic use.
- •Ipamorelin's selectivity mechanism is not fully elucidated.
PSI Verdict
SUPPORTED BY EVIDENCE
Both effectively stimulate GH release through the ghrelin receptor. Ipamorelin does so without significantly raising cortisol or prolactin — a consistent finding across multiple studies. GHRP-2 produces a stronger GH pulse but with concurrent cortisol and prolactin elevation.
NOT YET ESTABLISHED
Whether ipamorelin's cleaner profile translates to better long-term clinical outcomes has not been demonstrated. The clinical significance of GHRP-2's cortisol elevation during intermittent use is debated.
CONFIDENCE LEVEL
High for the selectivity difference — this is well-documented. Ipamorelin is the smarter choice for most GH optimization goals. GHRP-2 is the stronger stimulator if raw GH output is the only metric.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
GHRP-2
"GHRP-2 is the best all-around growth hormone peptide"Partially accurate
"GHRP-2 makes me extremely hungry"Supported by evidence
Ipamorelin
"Ipamorelin is the cleanest GH secretagogue with the fewest side effects"Plausible but unproven
"Combined with CJC-1295 it mimics natural GH pulsing"Plausible but unproven
"It helped with my joint pain and recovery"Anecdotal only
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
GHRP-2
Elevates cortisol and prolactin alongside GH. Strong appetite stimulation. More off-target effects than newer secretagogues.
Ipamorelin
Minimal off-target effects. Does not significantly raise cortisol or prolactin. Side effects are generally mild.
Ipamorelin has a markedly cleaner safety profile. GHRP-2 elevates cortisol (stress hormone) and prolactin (which can cause unwanted effects at sustained levels). For most applications, ipamorelin's selectivity is preferable.
WHAT THE RESEARCH SUGGESTS
Ipamorelin is the better option for most people due to its selectivity. GHRP-2 has niche applications where maximal GH stimulation or appetite stimulation is specifically desired.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.